Top

World Journal of Urology

Published in:

01-06-2010 | Original Article

Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

Authors: Christoph W. M. Reuter, Michael A. Morgan, Philipp Ivanyi, Martin Fenner, Arnold Ganser, Viktor Grünwald

Published in: World Journal of Urology | Issue 3/2010

Abstract

Background

There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may be effective in combination with docetaxel in this setting; however, the optimal docetaxel/carboplatin-based regimen is still unclear.

Aim of the study

We identified 43 consecutive patients with DRPC treated with carboplatin (AUC5 d1) and docetaxel (35 mg/m² d1, 8, 15 q4w i.v.) as a second-line or subsequent salvage chemotherapy until discontinuation of therapy due to disease progression or unacceptable toxicity.

Results

Decreased prostate-specific antigen (≥50% PSA) was observed in 22/43 (51.2%, 95% CI, 35.5, 66.7%) patients, with ≥90% reduction in 12/43 patients (27.9%). At the time of analysis, the median follow-up time for all patients was 10.4 months. Median progression-free survival (PFS) for all patients was 6.5 months (95% CI 4.1, 8.9), and median overall survival (OS) was 15.8 months (95% CI 12.1, 18.5). In PSA responders, PFS was 9.5 (95% CI 8.2, 19.0) months versus 3.3 (95% CI 2.6, 4.0) months in PSA non-responders (P < 0.0001; hazard ratio (HR) 0.108) and OS was 24.4 months (95% CI 19.5, 29.4) versus 7.8 (95% CI 5.2, 10.3) months (P = 0.001; HR 0.232). Established prognostic factors were associated with survival. This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (41.9/39.5%).

Conclusion

These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for patients with DRPC.

Shelley M, Harrioson C, Coles B et al (2010) Chemotherapy for hormone-refractory prostate cancer (review). Cochrane Database of systematc reviews 2006. Issue 4. Art. No.: CD005247. doi: 10.1002/14651858.CD005247.pub2

Garmey EG, Sartor O, Halabi S, Vogelzang NJ (2008) Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 6(118–22):127–132

Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 106:1041–1046CrossRefPubMed

Lainakis G, Nikos A, Gerassimos A et al (2008) Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer. Urology 71:1181–1185CrossRefPubMed

Nelius T, Klatte T, de Riese W, Haynes A, Filleur S (2009) Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol [Epub ahead of print]

Caffo O, Sava T, Comploj E et al (2010) Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol 28:152–156PubMed

Rosenberg JE, Weinberg VK, Kelly WK et al (2007) Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110:556–563CrossRefPubMed

Rosenberg JE, Ryan CJ, Weinberg VK et al (2009) Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 27:2772–2778CrossRefPubMed

Hussain A, DiPaola RS, Baron AD et al (2009) Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 20:492–497CrossRefPubMed

10.

Hahn NM, Zon RT, Jones T et al (2008) A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367. J Clin Oncol 26(S):16019

11.

Michaelson MD, Gilligan T, Oh W et al (2005) Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol 23(16(S)):4517

12.

Aragon-Ching JB, Jain L, Gulley JL et al (2009) Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 103:1636–1640CrossRefPubMed

13.

Dror Michaelson M, Regan MM, Oh WK et al (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20:913–920CrossRefPubMed

14.

Oh WK, Tay MH, Huang J (2007) Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 109:477–486CrossRefPubMed

15.

Sternberg CN, Petrylak DP, Sartor O et al (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27:5431–5438CrossRefPubMed

16.

Regan MM, O’Donnell EK, Kelly WK et al (2009) Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol 21:312–318CrossRefPubMed

17.

Nakabayashi M, Sartor O, Jacobus S et al (2008) Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 101:308–312CrossRefPubMed

18.

Ross RW, Beer TM, Jacobus S et al (2008) Prostate cancer clinical trials consortium. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112:521–526CrossRefPubMed

19.

Loriot Y, Massard C, Gross-Goupil M et al (2009) Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 20:703–708CrossRefPubMed

20.

Sella A, Yarom N, Zisman A, Kovel S (2009) Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 76:442–446CrossRefPubMed

21.

Dorff TB, Groshen SG, Wei D et al (2008) Interim results of a phase II trial of pemetrexed and oxaliplatin as 2nd/3rd line therapy in hormone refractory prostate cancer. J Clin Oncol 26(S):5139

22.

Scher HI, Halabi S, Tannock I et al (2008) Prostate cancer clinical trials working group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159CrossRefPubMed

23.

Scotté F, Tourani JM, Banu E et al (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23:4424–4429CrossRefPubMed

24.

Marangolo M, Bengala C, Conte PF et al (2006) Dose and outcome: the hurdle of neutropenia (Review). Oncol Rep 16:233–248PubMed

25.

Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44:4–10CrossRefPubMed

26.

Budman DR, Calabro A, Kreis W (2002) Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 13:1011–1016CrossRefPubMed

27.

Cabrespine A, Bay JO, Barthomeuf C et al (2005) In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. Anticancer Drugs 16:417–422CrossRefPubMed

28.

Wosikowski K, Lamphere L, Unteregger G et al (2007) Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 60:589–600CrossRefPubMed

29.

Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W (2002) Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59:1198–1211CrossRefPubMed

30.

Schertl S, Hartmann RW, Batzl-Hartmann C et al (2007) Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies. J Cancer Res Clin Oncol 133:153–167CrossRefPubMed

Title: Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
Authors: Christoph W. M. Reuter
Michael A. Morgan
Philipp Ivanyi
Martin Fenner
Arnold Ganser
Viktor Grünwald
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2010
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-010-0527-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

Abstract

Background

Aim of the study

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim of the study

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2010

Prognostic factors in renal cell carcinoma

Microvessel density estimate: friend or foe in the light of prostate vascular system complexity?

Clinical experience with survivin as a biomarker for urothelial bladder cancer

Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

Quantitative evaluation of electrodes for external urethral sphincter electromyography during bladder-to-urethral guarding reflex

Update on systemic therapies of metastatic renal cell carcinoma